Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors
Open Access
- 21 May 2010
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 116
Abstract
Background: p27Kip1 (p27) is an important negative regulator of the cell cycle and a putative tumor suppressor. The finding that a spontaneous germline frameshift mutation in Cdkn1b (encoding p27) causes the MENX multiple endocrine neoplasia syndrome in the rat provided the first evidence that Cdkn1b is a tumor susceptibility gene for endocrine tumors. Noteworthy, germline p27 mutations were also identified in human patients presenting with endocrine tumors. At present, it is not clear which features of p27 are crucial for this tissue-specific tumor predisposition in both rats and humans. It was shown that the MENX-associated Cdkn1b mutation causes reduced expression of the encoded protein, but the molecular mechanisms are unknown. To better understand the role of p27 in tumor predisposition and to characterize the MENX animal model at the molecular level, a prerequisite for future preclinical studies, we set out to assess the functional properties of the MENX-associated p27 mutant protein (named p27fs177) in vitro and in vivo. Results: In vitro, p27fs177 retains some properties of the wild-type p27 (p27wt) protein: it localizes to the nucleus; it interacts with cyclin-dependent kinases and, to lower extent, with cyclins. In contrast to p27wt, p27fs177 is highly unstable and rapidly degraded in every phase of the cell-cycle, including quiescence. It is in part degraded by Skp2-dependent proteasomal proteolysis, similarly to p27wt. Photobleaching studies showed reduced motility of p27fs177 in the nucleus compared to p27wt, suggesting that in this compartment p27fs177 is part of a multi-protein complex, likely together with the degradation machinery. Studies of primary rat newborn fibroblasts (RNF) established from normal and MENX-affected littermates confirmed the rapid degradation of p27fs177 in vivo which can be rescued by Bortezomib (proteasome inhibitor drug). Overexpression of the negative regulators microRNA-221/222 plays no role in regulating the amount of p27fs177 in RNFs and rat tissues. Conclusion: Our findings show that reduced p27 levels, not newly acquired properties, trigger tumor formation in rats, similarly to what has been observed in mice. The molecular characteristics of p27fs177 establish MENX as a useful preclinical model to evaluate compounds that inhibit p27 degradation for their efficacy against endocrine tumors.Keywords
This publication has 33 references indexed in Scilit:
- Germline mutations in the CDKN1B gene encoding p27Kip1 are a rare cause of multiple endocrine neoplasia type 1Clinical Endocrinology, 2009
- Assessment of p27 (cyclin‐dependent kinase inhibitor 1B) and aryl hydrocarbon receptor‐interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutationsClinical Endocrinology, 2009
- Post-translational regulation of the tumor suppressor p27KIP1Cellular and Molecular Life Sciences, 2008
- Argyrin A Reveals a Critical Role for the Tumor Suppressor Protein p27kip1 in Mediating Antitumor Activities in Response to Proteasome InhibitionCancer Cell, 2008
- Regulation of p27Kip1by miRNA 221/222 in GlioblastomaCell Cycle, 2007
- Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine NeoplasiaThe Journal of Clinical Endocrinology & Metabolism, 2007
- Discovery of an oncogenic activity in p27Kip1that causes stem cell expansion and a multiple tumor phenotypeGenes & Development, 2007
- Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferationThe EMBO Journal, 2007
- Germ-line mutations in p27
Kip1
cause a multiple endocrine neoplasia syndrome in rats and humansProceedings of the National Academy of Sciences, 2006
- A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppressionGenes & Development, 2006